S 48168 (ARM 210) for the Treatment of RYR1-related Myopathies (RYR1-RM)

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

August 25, 2020

Primary Completion Date

December 30, 2022

Study Completion Date

July 30, 2023

Conditions
RYR-1 Myopathy
Interventions
DRUG

S48168

A novel oral small molecule which is designed to repair leaky RYR1 channels

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

collaborator

National Institute of Nursing Research (NINR)

NIH

collaborator

Celerion

INDUSTRY

lead

Armgo Pharma, Inc.

INDUSTRY